Newsroom

Sorted by: Latest

-

MVLAND 2.0 lance « Studio Mode » et offre un contrôle de bout en bout, alors que la vidéo IA passe de la génération à la réalisation

NEW YORK--(BUSINESS WIRE)--MVLAND, la plateforme de création de clips musicaux par IA développée par Meitu, passe à la version 2.0 et lance officiellement son Studio Mode. Articulée autour d’un workflow créatif piloté par des agents IA et d’une analyse musicale professionnelle, cette mise à jour intègre l’ensemble du processus de production d’un clip musical — de la compréhension de la musique et du développement créatif au storyboard, à la génération des plans et au montage de postproduction —...
-

MVLAND 2.0 Launches “Studio Mode”, Bringing End-to-End Control as AI Video Moves From Generation to Direction

NEW YORK--(BUSINESS WIRE)--MVLAND, a Meitu-developed AI music video generator, has upgraded to Version 2.0 and officially launched its Studio Mode. Centered on an agent-driven creative workflow and professional music analysis, the update integrates the entire MV production pipeline — from music understanding and creative development to storyboarding, shot generation and post-editing — into one unified end-to-end workflow. Unlike conventional prompt-based AI tools that only generate fragmented c...
-

Samenvatting: Corcept kondigt positief CHMP-advies aan voor Europese markttoelating van Lifyorli® (Relacorilant)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), een bedrijf in de commerciële fase dat zich bezighoudt met het onderzoek naar en de ontwikkeling van geneesmiddelen voor de behandeling van ernstige endocrinologische, oncologische, metabole en neurologische aandoeningen door de werking van het hormoon cortisol te beïnvloeden, heeft vandaag bekendgemaakt dat het Comité voor geneesmiddelen voor menselijk gebruik (CHMP) van het Europees Geneesmiddelenbureau h...
-

Riassunto: Corcept annuncia l'opinione del CHMP che raccomanda l'autorizzazione dell'UE all'immissione in commercio per Lifyorli® (relacorilant)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), un'azienda di fase commerciale impegnata nella scoperta e nello sviluppo di farmaci per il trattamento di gravi patologie endocrine, oncologiche, metaboliche e neurologiche attraverso la modulazione degli effetti dell'ormone cortisolo, oggi ha annunciato che il Comitato per i Medicinali per Uso Umano (CHMP) dell’Agenzia europea per i medicinali (EMA) ha raccomandato l'approvazione da parte della Commissione...
-

Resumen: Corcept anuncia la opinión del CMUH en la que se recomienda la autorización de comercialización de la Unión Europea para Lifyorli® (relacorilant)

REDWOOD CITY, California--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), una empresa de fase comercial dedicada al descubrimiento y el desarrollo de medicamentos para el tratamiento de trastornos endocrinológicos, oncológicos, metabólicos y neurológicos graves mediante la modulación de los efectos de la hormona cortisol, anunció hoy que el Comité de Medicamentos de Uso Humano (CMUH) de la Agencia Europea de Medicamentos recomendó que la Comisión Europea apruebe relacorilant,...
-

Corcept veröffentlicht die Stellungnahme des CHMP mit einer Empfehlung für die EU-Zulassung für Lifyorli® (Relacorilant)

REDWOOD CITY, Kalif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) ist ein Unternehmen in der kommerziellen Phase, das sich mit der Erforschung und Entwicklung von Medikamenten zur Behandlung schwerer endokrinologischer, onkologischer, metabolischer und neurologischer Erkrankungen durch Modulation der Wirkung des Hormons Cortisol befasst. Es gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur der Europäischen Kommission (E...
-

Corcept annonce l'avis du CHMP recommandant l'autorisation de mise sur le marché de Lifyorli® (relacorilant) dans l'UE

REDWOOD CITY, Californie--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ : CORT), société au stade commercial spécialisée dans la découverte et le développement de médicaments qui modulent les effets du cortisol, destinés à traiter des maladies graves d'ordre endocrinologique, oncologique, métabolique et neurologique. La société a annoncé aujourd'hui que le Comité des médicaments à usage humain (CHMP) de l'Agence européenne des médicaments (EMA) a recommandé à la Commission européen...
-

AM Best Assigns Performance Assessment to Gridiron Insurance Underwriters, Inc. and Its Subsidiary

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned a Performance Assessment (assessment) of PA-2 (Excellent) to Gridiron Insurance Underwriters, Inc. (Gridiron) (Plantation, FL) and Signature Specialty, LP (Signature) (Plantation, FL). Signature is a wholly owned subsidiary of Gridiron. The outlook assigned to the assessment is stable.The assessment reflects Gridiron’s exceptional underwriting capabilities, excellent governance and internal controls, strong financial condition, excellent organ...
-

DICK’S Sporting Goods, Inc. (DKS) Investors: November 3, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against DICK’S Sporting Goods, Inc. (DICK’S) (NYSE: DKS) on behalf of those who purchased or acquired DICK’S common stock between September 8, 2025 and August 24, 2026, inclusive. The lawsuit is filed in the United States District Court for the Western District of Pennsylvania an...
-

AST SpaceMobile, Inc. (ASTS) Investors: November 13, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against AST SpaceMobile, Inc. (AST) (NASDAQ: ASTS) on behalf of those who purchased or acquired AST securities between March 4, 2025 and July 15, 2026, inclusive. The lawsuit is filed in the United States District Court for the Western District of Texas and is captioned Hunter v....